European Pharmaceutical Review

JULY 11, 2022

Funding of up to $30 million will support vaccine design, its development through Phase I trials and regulatory activities. . Confirmation of this funding is a testament to the team’s diligence and tenacity to highlight the potential offered by an RBD-nanoparticle vaccine.” . The novel vaccine, which is based on mosaic?

Vaccines 94

Vaccines Immunization 94

pharmaphorum

JANUARY 21, 2022

And as with many healthcare challenges, it is an issue that has been brought into sharp focus by COVID-19, during which we have seen huge investments in ground-breaking vaccines, quickly followed by inequities in access. Flawed funding model.

Insurance 52

Insurance Vaccines 52

pharmaphorum

JANUARY 31, 2023

Given the high price tags placed on many medications, it’s easy to understand why patients often feel that they are being taken advantage of. As patients experience first-hand the effectiveness reported in clinical trials, trust in the validity of these trials and the intentions of the pharmaceutical companies that fund them improves.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines Communication 52